Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells
| Autor: | Frank Thürmer, Peter Geigle, Moustapha Kassem, Christine Wallrapp, Anette Jork, Eric Thoenes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Materials science
Alginates Cell Pharmaceutical Science Mice Nude Bioengineering Neurotrophin-3 Endothelial Growth Factors Regenerative medicine chemistry.chemical_compound Mice Colloid and Surface Chemistry Glucuronic Acid Neurotrophin 3 Neurotrophic factors Glucagon-Like Peptide 1 Cell Line Tumor medicine Animals Humans Secretion Physical and Theoretical Chemistry Drug Carriers Mice Inbred BALB C biology Hexuronic Acids Organic Chemistry Mesenchymal stem cell Mesenchymal Stem Cells Cells Immobilized Recombinant Proteins Cell biology Vascular endothelial growth factor medicine.anatomical_structure chemistry Cell culture Immunology biology.protein |
| Zdroj: | Wallrapp, C, Thoenes, E, Thürmer, F, Jork, A, Kassem, M & Geigle, P 2013, ' Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells ', Journal of Microencapsulation, vol. 30, no. 4, pp. 315-24 . https://doi.org/10.3109/02652048.2012.726281 |
| DOI: | 10.3109/02652048.2012.726281 |
| Popis: | Glucagon-like peptide-1 (GLP-1) CellBeads are cell-based implants for the sustained local delivery of bioactive factors. They consist of GLP-1 secreting mesenchymal stem cells encapsulated in a spherically shaped immuno-isolating alginate matrix. A highly standardized and reproducible encapsulation method is described for the manufacturing of homogeneous CellBeads. Viability and sustained secretion was shown for the recombinant GLP-1 and the cell endogenous bioactive factors like vascular endothelial growth factor, neurotrophin 3 (NT-3) and glial cell line-derived neurotrophic factor. Manufacturing and quality control is performed in compliance with good manufacturing practice and fulfils all regulatory requirements for human clinical use. GLP-1 CellBeads combine the neuro- and cardioprotective properties of both GLP-1 and mesenchymal stem cells. First promising results were obtained from preclinical studies and an ongoing safety trial in humans but further studies have to prove the overall potential of CellBead technology in cell-based regenerative medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|